Elicio Therapeutics, Inc. (ELTX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies for cancer, specifically focusing on its lead candidate ELI-002 7P for pancreatic ductal adenocarcinoma (PDAC). This report covers the quarterly period ended September 30, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(10,083) | $(18,838) | $(31,853) | $(37,894) |
| Diluted EPS | $(0.60) | $(1.39) | $(2.09) | $(3.23) |
| Cash & Equivalents (End of Period) | $20,611 | $26,016 | $20,611 | $26,016 |
| Operating Cash Flow (9M) | $(30,155) | $(28,324) | $(30,155) | $(28,324) |
| Long-Term Debt (Net) | $9,720 | $20,034 | $9,720 | $20,034 |
| Warrant Liabilities | $3,877 | $2,828 | $3,877 | $2,828 |
Note: The company has no product revenue. Expenses are primarily Research & Development (R&D) and General & Administrative (G&A).
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss for Q3 2025 decreased by 46% compared to Q3 2024, driven by a significant reduction in non-cash losses related to warrant liabilities and lower clinical trial costs.
- Operating Expenses: Total operating expenses decreased by 22% in Q3 2025 ($8.0M) compared to Q3 2024 ($10.3M). R&D expenses dropped 30% due to patient progression in the Phase 2 study of ELI-002 7P.
- Debt Restructuring: In March 2025, the company converted a $20.0 million senior secured convertible note into common stock, reducing long-term debt significantly. In June 2025, the company issued a new $10.0 million senior secured promissory note.
- Financing Activity: The company raised approximately $31.8 million in net cash from financing activities over the nine months ended September 30, 2025, via at-the-market offerings, a registered direct offering, and the new promissory note.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. As of September 30, 2025, the company had an accumulated deficit of $226.0 million. Management estimates current cash will fund operations through the second quarter of 2026.
- Clinical Progress: The Independent Data Monitoring Committee (IDMC) recommended continuing the Phase 2 AMPLIFY-7P study without modifications following an interim review in August 2025. Final disease-free survival analysis is expected in the first half of 2026.
- Funding Needs: The company requires additional financing to continue development. Plans include public/private equity offerings, debt financing, or strategic collaborations. There is no assurance that funding will be available on acceptable terms.
- Risks: Key risks include the uncertainty of clinical trial results, the need for additional capital, volatility in warrant liability valuations, and reliance on third-party manufacturers and CROs.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "second quarter of 2026" funding estimate against current burn rates and potential delays in clinical milestones.
- Warrant Liability Volatility: Monitor the fair value of liability-classified warrants, which caused significant non-cash losses in prior periods and continue to impact the balance sheet.
- Debt Covenants: Review the terms of the June 2025 Promissory Note, including interest rates (Prime + 5.00%) and security interests (first priority lien on assets and IP).
- Dilution: Assess the impact of recent equity issuances (ATM, direct offerings, and warrant exercises) on existing shareholder ownership.
- Clinical Timeline: Confirm the timeline for the final analysis of the AMPLIFY-7P study and the potential for additional capital raises required before results are read out.